{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lyden P"],"funding":["NINDS NIH HHS"],"pagination":["2888-2895"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5134910"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["47(12)"],"pubmed_abstract":["<h4>Background and purpose</h4>Therapeutic hypothermia is a potent neuroprotectant approved for cerebral protection after neonatal hypoxia-ischemia and cardiac arrest. Therapeutic hypothermia for acute ischemic stroke is safe and feasible in pilot trials. We designed a study protocol to provide safer, faster therapeutic hypothermia in stroke patients.<h4>Methods</h4>Safety procedures and 4°C saline infusions for faster cooling were added to the ICTuS trial (Intravascular Cooling in the Treatment of Stroke) protocol. A femoral venous intravascular cooling catheter after intravenous recombinant tissue-type plasminogen activator in eligible patients provided 24 hours cooling followed by a 12-hour rewarm. Serial safety assessments and imaging were performed. The primary end point was 3-month m"],"journal":["Stroke"],"pubmed_title":["Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2)."],"pmcid":["PMC5134910"],"funding_grant_id":["P50 NS044148","P50 NS044227"],"pubmed_authors":["Shah Q","Ernstrom K","Janis S","Wilson J","Herial N","Tanner A","Marcolini EG","McBee D","Oddo M","Malik A","Khanolkar P","Brautigam R","Bruce N","Suys T","Jain S","Sohdi A","Cordier M","Moy C","Neil W","Mullin A","Dietrich D","Ovbiagele B","Gilmore EJ","Wilsom C","Lewandowski C","Lin F","Khanna A","Rzesiewicz T","Stern B","Wijman C","Kim E","Hamilton S","Lundell A","Merenda A","Jasak S","Dugan G","Yenari M","Kelly N","Holzer E","Shushrutha Hedna V","Escobar A","Poisson S","Bussinger P","Edwards NJ","Greer D","Kelley C","Rosado C","Raman R","Heim L","Piantadosi B","McCullough L","Chamorro A","Little A","Simpson J","O'Phelan K","Grotta J","Rapp K","Alexandrov A","Remillard S","Agarwal S","Schlick K","Guzik A","Rutledge N","Warren S","Broessner G","Chavez R","Brown D","Schmutzhard E","Hussain S","Jonczak K","Berry S","Velazquez A","Parker S","Meyer B","Modir R","Meyer D","Sisson A","Jurf J","So JS","Lewis P","Jane Hess M","Jimenez-Maggiora G","Altafullah I","Albright K","Diringer M","Michel P","Jones W","Concha M","Falo C","Hemmen T","Hess MJ","Becker K","Kizza R","Tafreshi G","Roldan A","Muranevici G","Song S","Escioglou E","Derdeyn C","Collaborators","Perez Barcena J","Cruz-Flores S","Smith C","Torretta S","Shell E","Miller JB","Dirnagl U","Eskandari A","Lyden P","Mayer S","Claassen J","Brown R"],"additional_accession":[]},"is_claimable":false,"name":"Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2).","description":"<h4>Background and purpose</h4>Therapeutic hypothermia is a potent neuroprotectant approved for cerebral protection after neonatal hypoxia-ischemia and cardiac arrest. Therapeutic hypothermia for acute ischemic stroke is safe and feasible in pilot trials. We designed a study protocol to provide safer, faster therapeutic hypothermia in stroke patients.<h4>Methods</h4>Safety procedures and 4°C saline infusions for faster cooling were added to the ICTuS trial (Intravascular Cooling in the Treatment of Stroke) protocol. A femoral venous intravascular cooling catheter after intravenous recombinant tissue-type plasminogen activator in eligible patients provided 24 hours cooling followed by a 12-hour rewarm. Serial safety assessments and imaging were performed. The primary end point was 3-month m","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Dec","modification":"2025-04-22T01:45:36.722Z","creation":"2019-03-27T02:30:36Z"},"accession":"S-EPMC5134910","cross_references":{"pubmed":["27834742"],"doi":["10.1161/STROKEAHA.116.014200","10.1161/strokeaha.116.014200"]}}